Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
Urokinase plasminogen activator (uPA) has been associated with aggressive behaviour and poor prognosis in human breast cancer, but there is no information on its expression in canine mammary tumours (CMT). uPA immunohistochemical expression was studied in 119 CMT (24 benign, 95 malignant) to investigate its relationship with clinical and histopathological parameters. Dogs with malignant mammary tumours (MMT) underwent a 2-year follow-up evaluation. MMT expressed significantly more uPA than benign tumours. In MMT, high uPA stromal expression was significantly associated with larger tumour size, high Ki-67 expression, invasive growth, high histological grade, regional lymph node metastases, development of distant metastases, and lower overall survival (OS) and disease-free survival (DFS). On the basis of these results, uPA could be considered a useful prognostic factor in dogs with MMT.
Santos
Andreia
A
Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Largo Professor Abel Salazar, 2, 4099-003 Porto, Portugal.
Lopes
Célia
C
Marques
Raquel M
RM
Amorim
Irina
I
Ribeiro
Jorge
J
Frias
Carlos
C
Vicente
Corália
C
Gärtner
Fátima
F
de Matos
Augusto
A
D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis*; D004283:Dog Diseases / Q000201:enzymology* / Q000473:pathology; D004285:Dogs; D005260:Female; D005500:Follow-Up Studies; D007150:Immunohistochemistry / Q000662:veterinary; D015674:Mammary Neoplasms, Animal / Q000201:enzymology* / Q000473:pathology; D011379:Prognosis; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis*
D014408:Biomarkers, Tumor; D014568:Urokinase-Type Plasminogen Activator